<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989832</url>
  </required_header>
  <id_info>
    <org_study_id>I10007</org_study_id>
    <nct_id>NCT01989832</nct_id>
  </id_info>
  <brief_title>Pharmaco-economical Study in Kidney Transplantation</brief_title>
  <acronym>EPHEGREN</acronym>
  <official_title>Pharmaco-economical Study in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of renal acute rejection in transplantation is reduced thanks to the optimized
      use of immunosuppressive drugs. However, graft survival at ten years has not improved since
      then; this may be explained in part by the toxicity of these drugs, viral infections, and
      other comorbidities (diabetes, cardiovascular diseases â€¦).

      According to transplant center, strategies for the combination of immunosuppressive drugs are
      different, and probably involve a difference in the global cost of patient management. There
      is no recommendation in France to establish similar practices.

      EPHEGREN is an observational, prospective, multicentric, pharmacoeconomic study for the renal
      transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Death</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to examine nature, dose and exposure in immunosuppresseurs.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">570</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Biological and clinical Data collected</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        renal transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the first month of renal graft, or patients already included in an other
             epidemiological French study (EPIGREN) in the 0-6 month period

          -  Men of women aged more than 18 years

          -  Patients able to exercise in writing their informed and free consent to participate to
             the biological collection

          -  Patients not opposing to collect their medical data

          -  Patients registered with a social security system

          -  Patients able to complete the questionnaires

        Exclusion Criteria:

          -  Patients aged less than 18 years and patients under guardianship

          -  Patients with a follow-up at another center other than those part of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cohort</keyword>
  <keyword>pharmaco-economic</keyword>
  <keyword>kidney</keyword>
  <keyword>transplantation</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

